Unknown

Dataset Information

0

Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors.

ABSTRACT:

SUBMITTER: Vistisen ST 

PROVIDER: S-EPMC7480801 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.
| S-EPMC7206932 | biostudies-literature
Unknown Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
| S-EPMC7121452 | biostudies-literature
Unknown Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19.
| S-EPMC8475700 | biostudies-literature
Unknown Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
| S-EPMC7206933 | biostudies-literature
Unknown Renin-angiotensin-aldosterone system and COVID-19 infection.
| S-EPMC7172808 | biostudies-literature
Unknown Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors.
| S-EPMC7692895 | biostudies-literature
Unknown Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension.
| S-EPMC8486159 | biostudies-literature
Unknown Safety and Efficacy of Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19 Population.
| S-EPMC8237039 | biostudies-literature
Unknown Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin-angiotensin-aldosterone system (RAAS) inhibitors: a systematic review.
| S-EPMC7988641 | biostudies-literature
Unknown Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study.
| S-EPMC7359535 | biostudies-literature